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Abstract
Results of a randomized controlled trial have suggested a
protective effect of selenium against prostate cancer. Few
other prospective studies have been conducted to confirm
or refute this. The association between prostate cancer
and baseline toenail selenium level was evaluated in the
Netherlands Cohort Study, conducted among 58,279 men,
aged 55–69 years at entry. In September 1986, the cohort
members completed a questionnaire on risk factors for
cancer and provided toenail clippings for determination
of baseline selenium status. After 6.3 years of follow-up,
540 incident prostate carcinoma cases and 1,211
subcohort members with complete toenail selenium data
were available for case-cohort analyses. In multivariate
survival analysis, an inverse association between toenail
selenium level and prostate cancer risk was observed.
Incidence rate ratios in increasing selenium quintiles were
1.00 (ref), 1.05, 0.69, 0.75, and 0.69 (95% confidence
interval, 0.48–0.99), respectively (P-trend  0.008). This
association persisted after exclusion of cases diagnosed
during early follow-up. The inverse association was more
pronounced in ex-smokers than current smokers, and
unclear in never-smokers. Analysis of effect modification
by intake of antioxidant vitamins C, E, and the
carotenoids -carotene, -carotene, -cryptoxanthin,
lycopene, and lutein/zeaxanthin showed a strong,
significant interaction with -cryptoxanthin, and to a
lesser extent with vitamin C. These results confirm the
hypothesis that higher selenium intake may reduce
prostate cancer risk. Future research on optimum dose
level is needed.
Introduction
It has been suggested that selenium may protect against cancer
(1), particularly because of its role as component of glutathione
peroxidase, an enzyme that is part of the cellular defense system
against oxidative damage (2). Whereas animal studies have
shown that selenium may have an inhibitory effect on carcino-
genesis in various experimental models (3), ecological studies
have also indicated an inverse association between dietary
selenium levels and cancer mortality, among which was pros-
tate cancer (4). After these early observations, prostate cancer
was not as often investigated in additional analytical epidemi-
ological studies as other cancer sites, but interest rose consid-
erably when secondary results of a randomized controlled trial
became available, showing a decreased risk of prostate cancer
after supplementation with selenium-enriched yeast (5).
New controlled trials have been initiated to examine
whether the result of the secondary analysis of Nutritional
Prevention of Cancer Trial (5) can be confirmed (6, 7). Mean-
while, it is informative to find out whether the inverse associ-
ation can also be found in case-control and cohort studies on
selenium levels in serum or toenails and prostate cancer risk (8).
Analytic epidemiological studies on selenium and cancer fre-
quently use biological markers of selenium status, such as
serum or toenail selenium levels, because estimation of dietary
selenium is considered unreliable (9). Toenail selenium has
gradually gained popularity as a biomarker of selenium status,
after observations that this marker is an indicator of long-term
selenium status (10, 11) and reflects differences in selenium
intake (12, 13).
Several observational studies on selenium and prostate
cancer have been reported since publication of the trial results
by Clark et al. (5), including five cohort studies, all from the
United States (14–18). Other recent studies were focused on
dietary selenium and prostate cancer risk (19–21).
In the United States, generally high serum selenium levels
are reported, whereas blood selenium levels in the Netherlands
are intermediate between those reported from New Zealand and
the United States, as is true for toenail selenium levels (22). We
studied the relationship between toenail selenium levels and
risk of prostate cancer in a cohort study in the Netherlands. The
potential effect modification by smoking and intake of antioxidant
vitamins C, E, and several carotenoids was also investigated.
Materials and Methods
The NLCS3. We will only briefly outline the study design
because this has been reported in detail elsewhere (23). The
NLCS was initiated in September 1986 and includes 58,279
men ages 55–69 years at the beginning of the study. The study
population originated from 204 municipal registries throughout
the country. At baseline, the cohort members completed a
mailed questionnaire on usual diet and potential confounders,
and provided toenail clippings. For reasons of efficiency in data
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processing and analysis, the case-cohort approach (24, 25) was
used. In a case-cohort approach, cases are derived from the
entire cohort (providing numerator information for calculation
of cancer incidence rates), whereas accumulated person years at
risk in the total cohort are estimated using a random subcohort
sample (providing denominator information for the rates). In
contrast to nested case-control sampling, this subcohort can be
used for multiple disease end points. The subcohort (n  1,688
men) was sampled directly after identification of all of the
cohort members and has been followed up biennially for vital
status information. Follow-up for incidence of prostate cancer
was established by computerized record linkage with all nine
cancer registries in the Netherlands and with the Dutch national
database of pathology reports (PALGA; 26). No subcohort
members were lost to follow-up, and completeness of follow-up
of cancer has been estimated to be at least 96% (27). The
present analysis is restricted to cancer incidence in 6.3 years of
follow-up, from September 1986 to December 1992, because
only information of toenail selenium status for cases diagnosed
until 1992 were available at the time of the analysis. After
excluding prevalent cases with cancer other than skin cancer, a
total of 1,630 subcohort men and 704 incident, microscopically
or histologically confirmed, primary prostate cancer cases were
available after 6.3 years of follow-up.
Exposure Status. The self-administered questionnaire on diet
has also been described in detail elsewhere (28). Mean daily
nutrient intakes were calculated using the computerized Dutch
food composition table (29). For carotenoids, a recently devel-
oped food composition database was used (30). About 7% of
the subjects were excluded because of incomplete or inconsis-
tent dietary questionnaire data (28). Toenail clippings had been
provided by 565 patients with prostate cancer (80.3%) and by
1282 (78.7%) subcohort members.
Toenail selenium analyses were carried out by the Inter-
faculty Reactor Institute at Delft University (Delft, the Neth-
erlands) using Instrumental Neutron Activation Analysis. This
method and the use in the NLCS have been described previ-
ously (31–33). Because of problems with the detection of
selenium in samples weighing 10 mg, and sometimes in
samples with very high calcium contents, 44 and 71 specimens
were excluded from the prostate cancer and subcohort groups,
respectively. Toenail selenium data were available for analysis
from 522 prostate cancer cases and 1211 subcohort members.
Statistical Analyses. To evaluate the potential influence of
prediagnostic cancer on toenail selenium levels we categorized
the cases according to the year of follow-up in which the
diagnosis was made. Mean toenail selenium levels of prostate
cancer cases were compared according to year of follow-up;
differences were tested using a t test. Toenail selenium levels
were categorized into quintiles according to the distribution in
the subcohort. Incidence RRs and corresponding 95% CIs for
prostate cancer were estimated using exponentially distributed
failure time regression models (34) with the Stata statistical
software package (35). SEs were estimated using the robust
Hubert-White sandwich estimator to account for additional
variance introduced by sampling from the cohort. This method
is equivalent to the variance-covariance estimator presented by
Barlow (36), and Lin and Ying (37). Because of skewedness to
the right, continuous data on toenail selenium concentrations
were normalized with a loge transformation. The RR was cal-
culated per standard unit (z-score) of toenail selenium levels.
This is comparable with an increment of 0.190 g/g selenium.
Variables that were considered as potential confounders
were age, a family history of prostate cancer, level of education,
and alcohol intake after results from previous analyses on
associations with prostate cancer risk in the NLCS (38, 39).
Because smoking is an important predictor of decreased sele-
nium levels (12, 31), analyses were additionally controlled for
smoking. Total energy and total fat intake were not considered
as potential confounding factors, because in this population no
association with prostate cancer risk was observed (40). The
same applies to vegetable and fruit consumption (41). Subgroup
analyses conditional on cigarette smoking status (never/ex/
current) were performed to evaluate interaction of selenium
with smoking. Previous studies (32, 42–44) have suggested a
potential interaction between vitamin levels and selenium re-
garding cancer risk. Therefore, we evaluated the interaction
with intake of antioxidant vitamins C, E, and the carotenoids
-carotene, -carotene, -cryptoxanthin, lycopene, and lutein/
zeaxanthin, by stratifying the results on high versus low intake
status of the subjects. Low and high were defined as the two
lowest quintiles and the two highest quintiles of intake of the
mentioned vitamins and carotenoids, respectively. Statistical
tests for interaction were based on Wald statistics. Advanced
prostate cancer cases (T3–4, M0; T0–4, and M1; Ref. 38) were
evaluated separately to test the hypothesis that selenium is more
strongly inversely related to advanced prostate tumors (14, 15).
Results
The mean ( SD) toenail selenium level in prostate cancer
cases was 0.530 ( 0.090) g/g, whereas in the male subcohort
members this value was 0.547 ( 0.126) g/g (Table 1). When
cases were categorized with respect to the year of follow-up in
which they were diagnosed, mean toenail selenium levels did
not show a trend across time. Early diagnosed cases did not
have significantly lower selenium values than cases diagnosed
in later years (Table 1).
Toenail selenium was inversely associated with prostate
cancer risk in age-adjusted analyses and multivariate analyses
(Table 2). The age-adjusted RR was 0.63 (95% CI, 0.45–0.90)
comparing highest to lowest selenium quintiles. After adjust-
ment for age, family history of prostate cancer, level of edu-
cation, and smoking, this RR was 0.69 (CI, 0.48–0.99) com-
paring highest to lowest selenium quintile (P-trend 0.008).
When toenail selenium was analyzed as continuous variable,
the RR was decreased by 10% for each increment of one
standard unit of toenail selenium (0.190 g/g). The reduced
prostate cancer risk appeared to be restricted to the three highest
quintiles of toenail selenium. Additional correction for alcohol
intake yielded similar results (data not shown); therefore, this
variable was not included in additional regression models.
Table 1 Toenail selenium levels (g/g) in prostate cancer cases according to
year of follow-up, NLCS 1986–1992
Mean (SD) selenium levels in male subcohort members were 0.547 (0.126)
g/g (n  1211).
Year of follow-up No. of
subjects
Toenail selenium level (g/g)
Mean SD P
All cases 540 0.530 0.090
1 52 0.524 0.093 0.193
2 50 0.515 0.077 0.079
3 72 0.526 0.090 0.196
4 106 0.534 0.082 0.535
5 95 0.520 0.095 0.044
6 124 0.539 0.095
reference7 41 0.551 0.087
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Analysis excluding cases from the first year of follow-up re-
sulted in essentially similar results (Table 2).
When analyses were conducted separately for subgroups
according to smoking status, the inverse association between
selenium and prostate cancer was significant among ex-smok-
ers (P-trend 0.003; Table 3). Whereas in current smokers the
RRs for second to fifth selenium quintiles were all decreased,
this inverse association was not as consistent as in ex-smokers
(P-trend  0.383). For never smokers, the RRs in quintiles 3
and 4 were appreciably lower than one, but this was not true for
quintile 2 and 5. There was no clear direction of the association
in this group. The interaction between selenium and smoking
status was statistically significant (P  0.026).
To evaluate effect modification of the association between
toenail selenium and prostate cancer risk by intake level of
antioxidant vitamins C and E, and several carotenoids, we also
tested whether the association with prostate cancer depended on
intake of these antioxidants (Table 4). The inverse selenium-
prostate cancer association was significant (P-trend  0.025)
and stronger in those with a relatively low vitamin C intake than
in those with a relatively high intake (P-trend  0.249); the P
for the test of interaction was 0.074. For vitamin E, there was
no evidence for interaction with selenium (P-interaction 
0.555). For -carotene and -carotene, the association between
selenium and prostate cancer was somewhat stronger in those
men with a relatively low intake of these carotenoids, but Ps for
the interaction tests were 0.320 and 0.204, respectively. A
strong interaction was found with intake of -cryptoxanthin
(P-interaction  0.005). In those with a relatively low -cryp-
toxanthin intake there was a strong inverse association, with the
RR for highest versus lowest selenium quintile estimated at
0.25 (CI, 0.12–0.54; P-trend 0.001). On the other hand, in
those with a relatively high -cryptoxanthin intake, there was
no significant association. For lutein/zeaxanthin, the associa-
tion between selenium and prostate cancer was also stronger
and more consistent in those with relatively low intakes of these
carotenoids, but no evidence of interaction was found (P-
interaction  0.780). For lycopene, there was no clear differ-
ence between the two intake strata (P-interaction  0.233).
With the exception of vitamin E and lycopene, these analyses
indicate that the selenium effect on prostate cancer was more
apparent in those subjects with a relatively low intake of dietary
antioxidants. Table 5 shows the RRs for toenail selenium in
case subgroups of localized and advanced prostate tumors. The
inverse association with selenium was seen in both groups
(Table 5).
Discussion
In this prospective cohort study with many prostate cancer
cases, a statistically significant inverse trend was found be-
tween the toenail selenium level and the risk of prostate cancer.
Toenail clippings have been used as measures of long-term
selenium intake. Toenail selenium level roughly reflected the
selenium intake in the previous 3 months to 1 year in a 1-year
feeding study (45), with a correlation coefficient of 0.67 be-
tween the two. In the NLCS, we could use prediagnostic toenail
selenium levels as measure of exposure. We showed that sele-
nium levels were not decreased in cases diagnosed during early
follow-up. Therefore, information bias is not likely to have
influenced our results. Furthermore, selection bias is also un-
likely because of the high completeness of follow-up of cases
and subcohort members (27, 46). The large number of prostate
cancer cases in the NLCS resulted in a relatively high power in
overall analyses, and we were also able to investigate different
subgroups based on tumor characterization (advanced cases) or
other characteristics of our study population (low and high
intake of vitamins/carotenoids). There are also some limitations
to our study. In the Nurses’ Health Study, a correlation coef-
ficient of 0.48 was found between toenail selenium levels for
Table 2 RR of prostate cancer according to toenail selenium levels, NLCS 1986–1992
Quintile of toenail Se
(boundaries in g/g)
Quintile median
(g/g)
All years of follow-up
First year excluded
RRb (95% CI)Cases in
cohort
Person years
in subcohort RR
a (95% CI) RRb (95% CI)
1 (0.467) 0.433 125 1444 1.00c 1.00c 1.00c
2 (0.467–0.514) 0.494 139 1457 1.03 (0.75–1.42) 1.05 (0.74–1.47) 1.05 (0.74–1.49)
3 (0.514–0.560) 0.537 104 1494 0.74 (0.53–1.03) 0.69 (0.48–1.00) 0.68 (0.47–1.00)
4 (0.560–0.616) 0.585 83 1437 0.71 (0.50–1.01) 0.75 (0.51–1.09) 0.76 (0.51–1.11)
5 (0.616) 0.663 89 1462 0.63 (0.45–0.90) 0.69 (0.48–0.99) 0.70 (0.48–1.01)
P for linear trend increment
in standard unitsd
0.001 0.008 0.012
0.87 (0.79–0.95) 0.90 (0.81–0.99) 0.91 (0.82–1.00)
a Adjusted for age (years, continuous).
b Adjusted for age (years), family history of prostate cancer (no/yes), number of cigarettes/day, years of cigarette smoking, level of education (low, medium, high).
c Reference category.
d z-scores based on In-transformed toenail selenium levels (increment of 0.190 g/g).
Table 3 RR of prostate cancer according to toenail selenium levels and smoking status, NLCS 1986–1992
Smoking status No. of cases
Quintile of toenail selenium (boundaries in g/g)
P
1 (0.467) 2 (0.514) 3 (0.560) 4 (0.616) 5 (0.616)
Nevera 72 1.00b 2.28 (0.80–6.47) 0.64 (0.23–1.76) 0.33 (0.09–1.18) 1.19 (0.48–2.92) 0.412
Exc 300 1.00b 0.87 (0.51–1.49) 0.53 (0.31–0.92) 0.79 (0.45–1.37) 0.46 (0.27–0.79) 0.003
Currentc 168 1.00b 0.88 (0.51–1.52) 0.95 (0.51–1.74) 0.53 (0.25–1.14) 0.97 (0.42–2.22) 0.383
a Adjusted for age (years), family history of prostate cancer (no/yes), level of education (low, medium, high).
b Reference category.
c Additionally adjusted for number of cigarettes/day, years of cigarette smoking.
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specimens taken 6 years apart (47). This moderate reliability
may have resulted in some misclassification of exposure. An-
other potential limitation is that we cannot exclude that residual
confounding from unidentified confounders has influenced our
results. By limiting our analysis to the follow-up period 1986–
1992, when prostate-specific antigen testing was not a common
screening routine in the Netherlands (48), we should not expect
a confounding effect of this factor.
Our observations that persons with an elevated toenail
selenium level have significantly lower prostate cancer risk are
in agreement with results of several other recent cohort studies,
analyzed in a nested case-control manner (14–16, 18), but not
all (17). Whereas these publications from United States studies
specifically dealt with prostate cancer, in earlier cohort studies
prostate cancer was studied with much smaller case numbers as
part of an initial overall cancer risk assessment. In these studies,
nonsignificant inverse associations were reported with prostate
cancer in United States studies (44, 49, 50) but not in a Finnish
cohort (1). Whereas most of the aforementioned studies were
based on serum selenium, the study of Yoshizawa et al. (14),
Helzlsouer et al. (16), and the NLCS were based on toenail
selenium. One case-control study using toenail selenium found
no association (51), whereas another case-control study on
plasma selenium observed an inverse association (52).
Our cohort study, which entails the largest number of
prostate cancer cases studied until now, did not find such a
strong inverse association as the other large cohort studies; the
relative risk in our upper selenium quintile was 0.69, whereas
relative risks of 0.4–0.5 have been reported in other studies for
the highest quintile (14–16). This may be the result of a smaller
exposure range and of the moderate selenium exposure in the
Netherlands compared with the United States (22, 31, 53). It
might be that stronger inverse associations can be found with
higher selenium exposure, although not all of the United States
studies support this (17). One cohort study (19) and most
case-control studies (20, 21, 54, 55) have investigated selenium
intake with respect to prostate cancer. Overall, no association
was found, but estimation of dietary selenium intake is consid-
ered unreliable (9, 31).
Several potential mechanisms have been put forward to
explain the anticarcinogenic effects of selenium. These include
antioxidant effects, inhibition of normal and malignant cell
proliferation and tumor growth, increased apoptosis, and stim-
ulation of the immune system and of DNA repair (56–61). The
antioxidant role of selenium has received most attention. There-
fore, we evaluated the effect of modification of smoking, be-
cause smoking induces oxidative stress (62, 63). Our finding
that the inverse association between selenium and prostate
cancer was present in smokers (particularly ex-smokers) was
partially concordant with results of Nomura et al. (15), although
they found a stronger association among current smokers. How-
ever, no association between serum selenium and prostate can-
Table 4 RRa of prostate cancer according to toenail selenium levels by category of vitamin or carotenoid intake, NLCS 1986–1992
Group No. of cases
Quintile of toenail selenium (boundaries in g/g)
P
1 (0.467) 2 (0.514) 3 (0.560) 4 (0.616) 5 (0.616)
Vitamin C intakeb
Low 182 1.00c 0.71 (0.39–1.31) 0.36 (0.18–0.71) 0.66 (0.35–1.25) 0.46 (0.24–0.89) 0.025
High 220 1.00c 1.06 (0.62–1.82) 1.28 (0.71–2.29) 0.77 (0.43–1.38) 0.80 (0.45–1.40) 0.249
Vitamin E intakeb
Low 204 1.00c 1.23 (0.69–2.20) 0.55 (0.30–1.01) 0.80 (0.42–1.52) 0.70 (0.38–1.28) 0.083
High 180 1.00c 0.80 (0.46–1.41) 0.85 (0.46–1.57) 0.76 (0.40–1.44) 0.61 (0.33–1.13) 0.147
-carotene intakeb
Low 213 1.00c 0.77 (0.43–1.37) 0.49 (0.27–0.89) 0.62 (0.35–1.13) 0.50 (0.27–0.92) 0.022
High 187 1.00c 1.33 (0.76–2.33) 1.19 (0.64–2.19) 0.93 (0.49–1.77) 0.62 (0.33–1.15) 0.058
-carotene intakeb
Low 214 1.00c 0.69 (0.38–1.24) 0.38 (0.20–0.70) 0.51 (0.27–0.95) 0.50 (0.27–0.92) 0.019
High 185 1.00c 1.15 (0.67–1.96) 1.13 (0.62–2.08) 0.84 (0.45–1.58) 0.62 (0.34–1.13) 0.070
-cryptoxanthin intakeb
Low 166 1.00c 0.89 (0.50–1.60) 0.44 (0.23–0.83) 0.53 (0.26–1.05) 0.25 (0.12–0.54) 0.001
High 241 1.00c 1.25 (0.71–2.18) 1.42 (0.79–2.54) 1.12 (0.62–2.04) 1.21 (0.68–2.16) 0.696
Lycopene intakeb
Low 182 1.00c 0.75 (0.40–1.39) 0.39 (0.20–0.75) 0.53 (0.28–1.02) 0.41 (0.21–0.80) 0.005
High 196 1.00c 1.06 (0.62–1.80) 1.05 (0.57–1.92) 0.49 (0.25–0.94) 0.49 (0.27–0.92) 0.003
Lutein/zeaxanthin intakeb
Low 206 1.00c 0.76 (0.41–1.39) 0.57 (0.30–1.05) 0.64 (0.34–1.20) 0.64 (0.34–1.21) 0.146
High 202 1.00c 1.24 (0.72–2.13) 0.89 (0.48–1.65) 1.04 (0.57–1.87) 0.79 (0.43–1.44) 0.363
a Adjusted for age (years), family history of prostate cancer (no/yes), number of cigarettes/day, years of cigarette smoking, level of education (low, medium, high).
b Low and high are defined as the two lowest quintiles and the two highest quintiles of intake, respectively. For vitamin C, the cutoff values for low and high were: 82.20,
101.30 mg/day; for vitamin E the corresponding values were: 11.86, 15.50 mg/day, for -carotene: 0.47, 0.67 mg/day, for -carotene: 2.38, 2.98 mg/day,
for -cryptoxanthin: 0.07, 0.13 mg/day, for lycopene: 0.55, 0.89 mg/day and for lutein/zeaxanthin: 2.15, 2.60 mg/day.
c Reference category.
Table 5 RRs for prostate cancer according to toenail selenium levels in
subgroups of localized (T0–2, M0) and advanced (T3–4, M0; T0–4, M1)
prostate tumors, NLCS 1986–1992
Quintile of
toenail selenium
(boundaries in g/g)
Localized tumors
(n  189)
Advanced tumors
(n  183)
RRa (95% CI) RRa (95% CI)
1 (0.467) 1.00b 1.00b
2 (0.467–0.514) 1.29 (0.79–2.10) 0.81 (0.50–1.33)
3 (0.514–0.560) 0.79 (0.46–1.35) 0.59 (0.35–1.00)
4 (0.560–0.616) 0.74 (0.42–1.33) 0.48 (0.27–0.86)
5 (0.616) 0.72 (0.42–1.24) 0.62 (0.37–1.05)
P for linear trend 0.043 0.020
a Adjusted for age (years), family history of prostate cancer (no/yes), number of
cigarettes/day, years of cigarette smoking, level of education (low, medium,
high).
b Reference category.
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cer was observed in the beta-Carotene and Retinol Efficacy
Trial, conducted among past and current smokers (17).
Yoshizawa et al. (14) reported that the inverse association with
selenium persisted among never and ex-smokers. Recently,
results from the Nutritional Prevention of Cancer Trial (53)
showed that the protective effect of selenium on total cancer
risk was more pronounced in ex-smokers. Unfortunately, they
did not specifically analyze prostate cancer in this respect.
Also from the antioxidant viewpoint, we evaluated possi-
ble effect modification by other dietary antioxidants, given
previous results on these interactions with respect to lung and
bladder cancer (32, 42). Overall, with the exception of vitamin
E, these analyses indicated that the decreased prostate cancer
risk associated with high toenail selenium was more apparent in
subjects with a relatively low intake of dietary antioxidant
vitamins and carotenoids than in those with higher intakes of
these nutrients. The interaction was most prominent with vita-
min C and -cryptoxanthin. The lack of interaction with vita-
min E is of interest because a new large prostate cancer pre-
vention trial (Selenium and Vitamin E Cancer Prevention Trial,
SELECT) has been started in which efficacy of selenium,
-tocopherol, and their combination in preventing prostate can-
cer will be studied, following promising results from separate
trials (5, 64). Our data indicate that the association of selenium
with prostate cancer does not depend on vitamin E intake level,
as was found by others (14, 19). Helzlsouer et al. (16) reported
dependency of the selenium effect on -tocopherol instead of
-tocopherol.
Whereas the observed interactions did not reach statistical
significance for most of the considered vitamins/carotenoids
(which can also be attributable to still low numbers in sub-
groups), the interaction with -cryptoxanthin intake was sig-
nificant. We reported earlier a positive association between
-cryptoxanthin and prostate cancer (65), as was found in other
studies (55, 66, 67). The currently observed interaction between
selenium and -cryptoxanthin in the NLCS suggests that sele-
nium only shows a protective effect regarding prostate cancer
when -cryptoxanthin intake is low. The data suggest also that
when -cryptoxanthin intake is high, selenium levels are not
influencing prostate cancer risk. Because only few studies have
evaluated specific carotenoids besides -carotene in relation to
prostate cancer (e.g. Ref. 68), and none have looked at inter-
actions between selenium and other carotenoids, it is difficult to
draw firm conclusions at this point. Additional epidemiological
studies are needed to study this observed interaction and, if
confirmed, laboratory studies are warranted to investigate the
possible mechanisms behind this interaction. Altogether, our
analyses of interaction with dietary antioxidants support the
role of selenium as antioxidant in anticarcinogenesis.
The selenium-prostate cancer association was observed
with both localized and advanced tumors. Nomura et al. (15)
found a stronger inverse association with advanced prostate
tumors than with localized tumors. In another cohort study,
only advanced prostate tumors were considered (14).
In conclusion, this study from the Netherlands confirms
earlier reports that subjects with elevated toenail selenium
levels have a reduced risk of prostate cancer. More randomized
controlled trials are needed to determine optimal dose levels
and to evaluate whether selenium may only be protective
among ex-smokers. Additional studies are also needed on in-
teractions with antioxidant vitamins and carotenoids, particu-
larly -cryptoxanthin.
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